VALSARTAN (valsartan) by Jubilant Therapeutics is angiotensin-converting enzyme (ace, kininase ii). Approved for hypertension, to lower blood pressure in adults, older and 2 more indications. First approved in 2015.
Drug data last refreshed 19h ago
angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Valsartan blocks…
Worked on VALSARTAN at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions